⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DTIL News
Precision BioSciences, Inc. Common Stock
Form 8-K
sec.gov
DTIL
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
businesswire.com
DTIL
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026
businesswire.com
DTIL
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026
businesswire.com
DTIL
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event
businesswire.com
DTIL
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
businesswire.com
TGTX
DTIL
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
businesswire.com
DTIL
TGTX
Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
businesswire.com
DTIL
Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
businesswire.com
DTIL
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
businesswire.com
DTIL